Search NLS News

A short distance separates the Nordics and the Baltic States but there are surprisingly few interactions between Nordic companies and those based in Latvia, Lithuania or Estonia. Is there limited scope for collaboration or could this be due to lack of awareness of potential opportunities? Ola Björkman went to the Life Sciences Baltics conference to […]

The company’s application to start the clinical phase I/IIa study, Tumorad-01, with the candidate drug 177Lu-SN201 in cancer patients has been approved. The first patient is expected to be included shortly, states the company. “We are very excited and strongly motivated to now start the first clinical study with Tumorad. The study is designed in […]

Nanoform Finland has granted AstraZeneca a global online STARMAP license. STARMAP is a digital AI version of the CESS technology that enables in-silico experiments to determine which molecules should be nanoformed. The license will enable AstraZeneca to screen molecules from drug discovery through to lifecycle management, describes Nanoform in a press release. Access to compound […]

The two collaborators have announced the launch of Biotech Heights, a new research hub that will explore food and materials production using bioprocessing to create useful products from living cells or cell components. “Lund University’s research mission in this area revolves around the exploration and advancement of scalable biotechnology, which we see as a transformative […]

A syndicate consisting of the Lundbeck Foundation BioCapital, EIR Ventures, EIFO and UCPH Ventures, has made an investment in the Danish biotech company Dania Therapeutics. “We are stepping in with strong partners at an early stage, where we can help build and further develop Dania Tx. We know from previous collaborations that Kristian Helin stands […]

The program is supported and partly financed by the American food and Drug Administration FDA, with the aim that more technological innovation designed for children will reach the market and patients. The company’s medical device, Neola, has been selected as a promising innovation with the potential to improve neonatal intensive care from the first day […]

Ultimovacs has announced the results from the NIPU clinical trial, an investigator-initiated, randomized, multi-center, open-label Phase II clinical trial for second-line treatment in patients with malignant mesothelioma. The data presented as a late-breaking abstract at the ESMO Congress, shows that Ultimovacs’ cancer vaccine UV1, in combination with ipilimumab and nivolumab, demonstrated a statistically significant and […]

Life sciences has experienced remarkable transformations in recent years, driven by cutting-edge research, technological advancements, and the pursuit of improved health outcomes. The number of early and mid-stage biotech companies has increased substantially in recent decades. There is one, in our view, major obstacle to unleashing the potential of the life science industry in Norway: […]

The company has announced results from an extended pooled analysis using data from the 17-HMedIdeS-14 study, an international long-term follow-up study of patients who have received a kidney transplant following desensitization with imlifidase. The results showed sustained positive outcomes out to 5 years in the majority of highly sensitized patients who received an imlifidase-enabled kidney […]

CombiGene will regain the global rights for the epilepsy project CG01 from Spark Therapeutics by January 12, 2024. The collaboration agreement between CombiGene and Spark Therapeutics, which was signed in October 2021, shall be terminated because of a strategic decision by Spark Therapeutics to deprioritize the further development of CG01 in epilepsy as part of […]